DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Trial Details

NCT ID

NCT04567420

Phase

PHASE2

Sponsor

Criterium, Inc.

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

• Palbociclib
• Fulvestrant
• Adjuvant Therapy

Locations (sample)

• Tucson, Arizona, United States|32.22174,-110.92648
• Los Angeles, California, United States|34.05223,-118.24368
• Los Angeles, California, United States|34.05223,-118.24368
• Aurora, Colorado, United States|39.72943,-104.83192
• Golden, Colorado, United States|39.75554,-105.2211

Key Eligibility Criteria

• High risk for recurrence HER-2 negative, ER positive invasive breast cancer. For this study, ER positivity is defined as equal to or greater than 1…
• Patients may have completed adjuvant endocrine therapy and are within 7 years since the date of their definitive breast surgery, or may be currentl…
• High risk for recurrence is defined as any one of the following (these criteria apply equally to both patients who underwent surgery first and thos…
• (iii) Diagnosis of Inflammatory Breast Cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.